Text Marked By [* * *] Has Been Omitted Pursuant To A Request For Confidential Treatment And Was Filed Separately With The Securities And Exchange Commission. AMENDED AND RESTATED MANUFACTURING SERVICES AGREEMENTManufacturing Services Agreement • March 12th, 2018 • Iovance Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Amended and Restated Manufacturing Services Agreement (this “Agreement”) is made as of December 18, 2017 (the “Effective Date”) by and between WuXi AppTec, Inc., a corporation organized under the laws of Delaware having a place of business at 4751 League Island Blvd., Philadelphia, PA 19112 (“Company”), and Iovance Biotherapeutics, Inc. (f.d.b.a. Lion Biotechnologies, Inc.), a Delaware corporation having its principal place of business at 999 Skyway Road, Suite 150, San Carlos, CA 94070 (“Iovance”) (each of Company and Iovance, a “Party” and, collectively, the “Parties”).
SECOND AMENDMENT TO THE STRATEGIC ALLIANCE AGREEMENT Effective Date: February 16, 2018Alliance Agreement • March 12th, 2018 • Iovance Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
THIS SECOND AMENDMENT TO THE STRATEGIC ALLIANCE AGREEMENT (this “Amendment”), is entered into by and between Iovance Biotherapeutics, Inc., a Delaware corporation and successor in interest to Lion Biotechnologies, Inc., with a place of business located at 999 Skyway Road, Suite 150, San Carlos, CA 94070 (“Iovance”), and The University of Texas M. D. Anderson Cancer Center, with a place of business located at 1515 Holcombe Blvd., Houston, TX 77030 (“MD Anderson”), a member institution of The University of Texas System, as of the date set forth above (the “Effective Date”). Iovance and MD Anderson may each be referred to as a “Party” or together, the “Parties”. Unless otherwise defined in this Amendment, all capitalized terms shall have the meaning ascribed to them in the Original Agreement (as defined hereinafter).
FIRST AMENDMENT TO THE STRATEGIC ALLIANCE AGREEMENT Effective Date: August 2, 2017Alliance Agreement • March 12th, 2018 • Iovance Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT TO THE STRATEGIC ALLIANCE AGREEMENT (this “Amendment”), is entered into by and between Iovance Biotherapeutics, Inc., a Delaware corporation, successor in interest to Lion Biotechnologies, Inc., with a place of business located at 999 Skyway Road, Suite 150, San Carlos, CA 94070 (“Iovance”), and The University of Texas M. D. Anderson Cancer Center, with a place of business located at 1515 Holcombe Blvd., Houston, TX 77030 (“MD Anderson”), a member institution of The University of Texas System, as of the date set forth above (the “Effective Date”). Iovance and MD Anderson may each be referred to as a “Party” or together, the “Parties”.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 12th, 2018 • Iovance Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • California
THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) dated August 7, 2016 by and between Lion Biotechnologies, Inc., a Nevada corporation (the “Company”), and Frederick Vogt (“Executive”) (either party individually, a “Party”; collectively, the “Parties”).
